Clinical Trials | S2212; Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
The University of Virginia seeks adult women ages 18 years and older with Early-Stage Triple Negative Breast Cancer (TNBC) for a clinical trial. If you participate in this study, you will be randomized (assigned by chance) to one of two treatment arms: - Arm I includes usual chemo-immunotherapy treatment; paclitaxel IV, carboplatin IV, and pembrolizumab IV. Then you will receive doxorubicin IV, cyclophosphamide IV, and pembrolizumab IV. You will then undergo surgery and may receive pembrolizumab after your surgery. - Arm II includes shorter chemo-immunotherapy treatment; docetaxel IV, carboplatin IV, and pembrolizumab IV. You will then undergo surgery and may receive pembrolizumab after surgery. This study involves blood draw, tissue collection, physical examination, and an echocardiogram (ECHO). Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. Additional information can be found here: https://clinicaltrials.gov/study/NCT05929768